A review of the therapeutic agents used in the management of polycythaemia vera

Hematological Oncology

Volumn 25, Issue 2, 2007, Pages 58-65

  McMullin, Mary Frances ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Acute Leukaemia; Hydroxycarbamide; Interferon; Myelofibrosis; Polycythaemia vera; Thromboembolic agents

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; BUSULFAN; CARBOQUONE; CHLORAMBUCIL; DIPYRIDAMOLE; HYDROXICARBAMIDE; HYDROXYUREA; IMATINIB; MELPHALAN; PHOSPHORUS 32; PIPOBROMAN; PLACEBO; THROMBOXANE B2; TIOGUANINE; UNCLASSIFIED DRUG; URACIL;

ACUTE LEUKEMIA; ANEMIA; ARTERY THROMBOSIS; ARTHRALGIA; BLEEDING; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOPENIA; DIARRHEA; DISEASE MANAGEMENT; DOSE RESPONSE; FEVER; FLU LIKE SYNDROME; FLUID RETENTION; HEADACHE; HUMAN; INTERMETHOD COMPARISON; LOW DRUG DOSE; MYALGIA; MYELOFIBROSIS; PHLEBOTOMY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; STOMACH PAIN; TACHYCARDIA; THROMBOSIS;

HEMATOCRIT; HUMANS; HYDROXYUREA; INTERFERONS; PIPOBROMAN; POLYCYTHEMIA VERA; RANDOMIZED CONTROLLED TRIALS;

EID: 34250839488     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.809     Document Type: Review

References (72)

1. Thomas DJ, du Boulay GH, Marshall J, et al. Cerebral blood-flow in polycythaemia. Lancet 1977 Jul 23; 2(8030): 161-163.
2. Pearson TC, Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet 1978 Dec 9; 2(8102): 1219-1222.
3. Berk PD, Wassermann LR, Fruchtman SM, Goldberg JT. Treatment of polycythaemia vera, a summary of clinical trends conducted by the polycythaemia vera sub-group. In: Wasserman LP, Berk PD (eds). Treatment of polycythaemia vera, a summary of clinical trends conducted by the polycythaemia vera study group. W.B. Saunders: Philadelphia, 1995; 166-194.
4. Tartaglia AP, Goldberg JD, Berk PD, Wasserman LR. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin. Hematol 1986 Jul; 23(3): 172-176.
5. Najean Y, Dresch C, Rain JD. The very-long-term course of polycythaemia: a complement to the previously published data of the Polycythaemia Vera Study Group. Br. J. Haematol 1994 Jan; 86(1): 233-235.
6. Najean Y, Rain JD. The very long-term evolution of polycythemia vera: an analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981. Semin. Hematol 1997 Jan; 34(1): 6-16.
7. Najean Y, Rain JD. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. Blood 1997 Apr 1; 89(7): 2319-2327.
8. Najean Y, Rain JD. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 1997 Nov 1; 90(9): 3370-3377.
9. Pearson TC, Green AR, Reilly JT, Harrison G. Leukemic transformation in polycythemia Vera. MPD(UK) Study Group. Blood 1998 Sep 1; 92(5): 1837-1838.
10. Cooperative Group European Organization for Research on Treatment of Cancer (EORTC). Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. "Leukemia and Hematosarcoma'. Br. J. Cancer 1981 Jul; 44(1): 75-80.
11. Low-dose aspirin in polycythaemia vera: a pilot study. Gruppo Italiano Studio Policitemia (GISP). Br. J. Haematol 1997 May; 97(2): 453-456.
12. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N. Engl. J. Med 2004 Jan 8; 350(2): 114-124.
13. Donovan PB, Kaplan ME, Goldberg JD, et al. Treatment of polycythemia vera with hydroxyurea. Am. J. Hematol 1984; 17(4): 329-334.
14. Kaplan ME, Mack K, Goldberg JD, Donovan PB, Berk PD, Wasserman LR. Long-term management of polycythemia vera with hydroxyurea: a progress report. Semin. Hematol 1986 Jul; 23(3): 167-171.
15. Fruchtman SM, Mack K, Kaplan ME, Peterson P, Berk PD, Wasserman LR. From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Semin. Hematol 1997 Jan; 34(1): 17-23.
16. Tatarsky I, Sharon R. Management of polycythemia vera with hydroxyurea. Semin. Hematol 1997 Jan; 34(1): 24-28.
17. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N. Engl. J. Med 1995 Apr 27; 332(17): 1132-1136.
18. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N. Engl. J. Med 2005 Jul 7; 353(1): 33-45.
19. Halsey C, Roberts IA. The role of hydroxyurea in sickle cell disease. Br. J. Haematol 2003 Jan; 120(2): 177-186.
20. Hanft VN, Fruchtman SR, Pickens CV, Rosse WF, Howard TA, Ware RE. Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood 2000 Jun 1; 95(11): 3589-3593.
21. Sterkers Y, Preudhomme C, Lai JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998 Jan 15; 91(2): 616-622.
22. Modan K, Lilienfeld AM. Leukaemogenic effect of ionising irradiation treatment in Polycythaemia. Lancet 1964; 2: 439.
23. Osgood EE. Contrasting incidence of acute monocytic and granulocytic leukemias in p32 treated patients with polycythemia vera and chronic lymphocytic leukemia. J Lab Clin Med 1964; 64: 560-573.
24. Harman JB, Ledlie EM. Survival of polycythaemia vera patients treated with radioactive phosphorus. Br. Med. J 1967 Apr 15; 2(545): 146-148.
25. Halnan KE, Russell MH. Polycythaemia Vera comparison of survival and cases of death in patients managed with and without radiotherapy. Lancet 1965; 11: 760.
26. Monto RW, Tenpas A, Battle JD Jr, Rohn RJ, Louis J, Louis NB. A-8103. In Polycythaemia 1964 Nov 30; 190: 833-836.
27. Boivin P. Indications, procedure and results for the treatment of polycythaemia vera by bleeding, pipobroman and hydroxyurea. Nouv. Rev. Fr. Hematol 1993; 35(5): 491-498.
28. Castello G, Lerza R, Cerruti A, Cavallini D, Bogliolo G, Pannacciulli I. The in vitro and in vivo effect of recombinant interferon alpha-2a on circulating haemopoietic progenitors in polycythaemia vera. Br. J. Haematol 1994 Jul; 87(3): 621-623.
29. Sacchi S, Leoni P, Liberati M, et al. A prospective comparison between treatment with phlebotomy alone and with interferon-alpha in patients with polycythemia vera. Ann. Hematol 1994 May; 68(5): 247-250.
30. Finelli C, Gugliotta L, Gamberi B, Vianelli N, Visani G, Tura S. Relief of intractable pruritus in polycythemia vera with recombinant interferon alfa. Am. J. Hematol 1993 Aug; 43(4): 316-318.
31. Muller EW, de Wolf JT, Egger R, et al. Long-term treatment with interferon-alpha 2b for severe pruritus in patients with polycythaemia vera. Br. J. Haematol 1995 Feb; 89(2): 313-318.
32. Waysbort A, Giroux M, Mansat V, Teixeira M, Dumas JC, Puel J. Experimental study of transplacental passage of alpha interferon by two assay techniques. Antimicrob. Agents Chemother 1993 Jun; 37(6): 1232-1237.
33. Logue GL, Gutterman JU, McGinn TG, Laszlo J, Rundles RW. Melphalan therapy of polycythemia vera. Blood 1970 Jul; 36(1): 70-86.
34. Toh BT, Gregory SA, Knospe WH. Acute leukemia following treatment of polycythemia vera and essential thrombocythemia with uracil mustard. Am. J. Hematol 1988 May; 28(1): 58-60.
35. Milligan DW, Thein SL, Roberts BE. Secondary treatment of polycythemia rubra vera with 6-thioguanine. Cancer 1982 Sep 1; 50(5): 836-839.
36. Higuchi T, Okada S, Mori H, Niikura H, Omine M, Terada H. Leukemic transformation of polycythemia vera and essential thrombocythemia possibly associated with an alkylating agent. Cancer 1995 Jan 15; 75(2): 471-477.
37. Louis T. Treatment of polycythaemia vera with busulphan (Myeleran). JAMA 1958; 188: 1880-1882.
38. Messinezy M, Pearson TC, Prochazka A, Wetherley-Mein G. Treatment of primary proliferative polycythaemia by venesection and low dose busulphan: retrospective study from one centre. Br. J. Haematol 1985 Dec; 61(4): 657-666.
39. Thiele J, Kvasnicka HM, Fuchs N, Brunnbauer K, Volkwein N, Schmitt-Graeff A. Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. an immunohistochemical and morphometric study of sequential trephine biopsies. Haematologica 2003 Oct; 88(10): 1130-1138.
40. Anagrelide Study Group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am. J. Med 1992 Jan; 92(1): 69-76.
41. Petitt RM, Silverstein MN, Petrone ME. Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin. Hematol 1997 Jan; 34(1): 51-54.
42. Oehler L, Jaeger E, Eser A, Sillaber C, Gisslinger H, Geissler K. Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythemia vera in vitro. Blood 2003 Sep 15; 102(6): 2240-2242.
43. Silver RT. Imatinib mesylate (Gleevec(TM)) reduces phlebotomy requirements in polycythemia vera. Leukemia 2003 Jun; 17(6): 1186-1187.
44. Jones AV, Silver RT, Waghorn K, et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood 2006 Apr 15; 107(8): 3339-3341.
45. McMullin MF, Bareford D, Campbell P, et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br. J. Haematol 2005 Jul; 130(2): 174-195.
46. West WO. Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period. South. Med. J 1987 Mar; 80(3): 323-327.
47. Lofvenberg E, Wahlin A. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur. J. Haematol 1988 Oct; 41(4): 375-381.
48. Weinfeld A, Swolin B, Westin J. Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur. J. Haematol 1994 Mar; 52(3): 134-139.
49. Nand S, Stock W, Godwin J, Fisher SG. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Am. J. Hematol 1996 May; 52(1): 42-46.
50. Nielsen I, Hasselbalch HC. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Am. J. Hematol 2003 Sep; 74(1): 26-31.
51. Szur L, Smith MD. Red-cell production and destruction in myelosclerosis. Br. J. Haematol 1961; Apr; 7: 147-168.
52. Tubiana M, Flament R, Attie E, Hayat M. A study of hematological complications occuring in patients with polycythaemia vera treated with 32P. Blood 1968; 32: 536-548.
53. Lawrence JH. Relationship to splenic myeloid metaplasia and therapeutic radiation base. Ann Intern Med 1969; 70: 363-371.
54. Meuret G, Hoffmann G, Gmelin R. 32P-therapy in polycythemia vera. Klin. Wochenschr 1975 Jun 1; 53(11): 519-521.
55. Randi ML, Fabris F, Varotto L, Rossi C, Macri C, Girolami A. Haematological complications in polycythaemia vera and thrombocythaemia patients treated with radiophosphorus (32P). Folia Haematol. Int. Mag. Klin. Morphol. Blutforsch 1990; 117(3): 461-467.
56. Brandt L, Anderson H. Survival and risk of leukaemia in polycythaemia vera and essential thrombocythaemia treated with oral radiophosphorus: are safer drugs available? Eur. J. Haematol 1995 Jan; 54(1): 21-26.
57. Najman A, Stachowiak J, Parlier Y, Gerin NC, Buhamel C. Pipobroman Therapy of Polycythaemia Vera. Blood 1982; 59: 890-894.
58. Brusamolino E, Salvaneschi L, Canevari A, Bernasconi C. Efficacy trial of pipobroman in polycythemia vera and incidence of acute leukemia. J. Clin. Oncol 1984 Jun; 2(6): 558-561.
59. Petti MC, Spadea A, Avvisati G, et al. Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991). Leukemia 1998 Jun; 12(6): 869-874.
60. Passamonti F, Brusamolino E, Lazzarino M, et al. Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients. Haematologica 2000; Oct; 85(10): 1011-1018.
61. Kiladjian JJ, Gardin C, Renoux M, Bruno F, Bernard JF. Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. Hematol. J 2003; 4(3): 198-207.
62. Cacciola E, Giustolisi R, Guglielmo P, Di Raimondo F, Cacciola E, Calogero RD. Recombinant interferon alpha in the treatment of polycythemia vera. Blood 1991 Jun 15; 77(12): 2790-2791.
63. Turri D, Mitra ME, Di Trapani R, Lipari MG, Perricone R, Cajozzo A. Alpha-interferon in polycythemia vera and essential thrombocythemia. Haematologica 1991 Jan-Feb; 76(1): 75-77.
64. Cimino R, Rametta V, Matera C, Mele G, Mettivier V, Ferrara F. Recombinant interferon alpha-2b in the treatment of polycythemia vera. Am. J. Hematol 1993 Nov; 44(3): 155-157.
65. Papineschi F, Bucalossi A, Capochiani E, et al. Recombinant alpha 2a interferon and polycythemia vera: clinical results and biological evaluation by means of Fourier-transform infrared microspectroscopy. Eur. J. Haematol 1994 Oct; 53(4): 213-217.
66. Taylor PC, Dolan G, Ng JP, Paul B, Collin R, Reilly JT. Efficacy of recombinant interferon-alpha (rIFN-alpha) in polycythaemia vera: a study of 17 patients and an analysis of published data. Br. J. Haematol 1996 Jan; 92(1): 55-59.
67. Silver RT. Interferon alfa: effects of long-term treatment for polycythemia vera. Semin.Hematol 1997 Jan; 34(1): 40-50.
68. Foa P, Massaro P, Caldiera S, et al. Long-term therapeutic efficacy and toxicity of recombinant interferon-alpha 2a in polycythaemia vera. Eur. J. Haematol 1998 May; 60(5): 273-277.
69. Ozturk A, Gunay A, Uskent N. Therapeutic efficacy of recombinant interferon-alpha in polycythaemia vera. Acta Haematol 1998; 99(2): 89-91.
70. Stasi R, Venditti A, Del Poeta G, et al. Role of human leukocyte interferon-alpha in the treatment of patients with polycythemia vera. Am. J. Med. Sci 1998 Apr; 315(4): 237-241.
71. Heis N, Rintelen C, Gisslinger B, Knobl P, Lechner K, Gisslinger H. The effect of interferon alpha on myeloproliferation and vascular complications in polycythemia vera. Eur. J. Haematol 1999 Jan; 62(1): 27-31.
72. Lawrence JH. Nuclear Physics and therapy: Preliminary report on a new method for the treatment of Lukemia and Polycythemia Radiology 1940; 35(1): 51-60.